Global Biologics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564281
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Celgene Corporation
  • Eli Lilly and Company
  • MORE
Biologics Market Growth, Future Prospects, and Competitive Analysis, 2018 -2026 the biologics market was valued at US$ 254.9 Bn in 2017, and expected to reach US$ 580.5 Bn by 2026 at a CAGR of 9.5 % during the forecast period from 2018 to 2026.

Market Insights
Global biologics market exhibits remunerative growth during the forecast period from 2018 to 2026 due to presence of around 800 biologics in pipeline. The growth attributed is due to incessant expansion in product portfolio with increasing demand for biologics across the globe. Rising prevalence of chronic diseases, unremitting research and development activities and continuous investment in biologics contribute to the overall market growth. According to World Health Organization (WHO), by 2020 chronic diseases would account for 75% of deaths globally. Cancer, autoimmune diseases, and diabetes contribute above 60% of the overall biologics market. In 2016, approximately 50% of new molecular entities approved by the FDA were biologics. Continuous development in cellular & gene therapy further catalyzes the market owing to its high efficacy and therapeutic outcome. CAR-T cell therapies are the latest therapies approved by the FDA for oncology indications.

The therapeutic expansion of biologics across various indications such as asthma, allergic conditions, dyslipidemia and other non-traditional disease areas attributed to the forecasted growth. However, the expedited expansion of biosimilars has a negative impact on the overall growth of biologics market. Biosimilars being cost-effective with similar efficacy would gain higher demand in developing countries. Biologics approved in the U.S comprise longer patent protection in comparison to those approved in Europe. Additionally, EMA has less stringent policies for biosimilars in comparison to the U.S FDA, thus North America owns larger market share than Europe and will maintain its dominance throughout the forecast period. Growing prevalence of cancer, autoimmune diseases & diabetes, presence of leading market players, and continuous research activities drive the North American market. Asia Pacific is the fastest growing market accounting to double digit CAGR during the forecast period. Expansion of international players in developing nations contribute to the biologics market growth in this region. Novartis AG wishes to launch its FDA approved treatment Kymriah in Japan. However, discussions on the pricing of the treatment in Japan is still under negotiations with Ministry of Health, and Labor & Welfare (MHLW).

Biologics entering the market contest with similar indications and with more or less similar mechanism of action. Biologics market is thus highly competitive comprising established and leading market players such as Abbvie, Inc., Amgen, Inc., AstraZeneca Plc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Pfizer, Inc., Roche Holding AG, Sanofi S.A and Takeda Pharmaceutical Co., Ltd.

Key Market Movements:
  • Globally, biologics market continues to witness a lucrative growth with a CAGR of 9.5% for the period from 2018 to 2026
  • Presence of an extensive product portfolio and above 800 pipeline molecules, contributed to the overall growth of the market
  • Among all the products available, recombinant therapeutic proteins maintains dominancy comprehending larger market share during the period from 2016 to 2026
  • The introduction of new cellular and gene therapy namely CAR-T cell provides better therapeutic outcome. Furthermore, research activities in this area contributes to the overall market growth during the forecast period.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Celgene Corporation
  • Eli Lilly and Company
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I-Secondary Research
1.4.2. Phase II-Primary Research
1.4.3. Phase III-Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Biologics Market Portraiture
2.2. Global Biologics Market, by Product, 2017 (US$ Bn)
2.3. Global Biologics Market, by Disease, 2017 (US$ Bn)
2.4. Global Biologics Market, by Geography, 2017 (US$ Bn)

Chapter 3. Global Biologics Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Growing Prevalence Of Chronic Conditions
3.2.1.2. Increased Investment in Research Activities
3.2.2. Market Challenges
3.2.2.1. Growth of Biosimilars
3.2.2.2. Challenge 2
3.2.3. Market Opportunities
3.2.3.1. Strong Pipeline Candidates
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Biologics Market, by Product, 2016-2026 (US$ Bn)
4.1. Overview
4.2. Recombinant Therapeutic Proteins
4.2.1. Monoclonal Antibodies
4.2.2. Hormones
4.2.3. Cytokines
4.2.4. Enzymes
4.3. Blood & Blood components
4.4. Cellular & Gene Therapy
4.5. Vaccines

Chapter 5. Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
5.1. Overview
5.2. Oncology
5.2.1. Breast Cancer
5.2.2. Leukemia
5.2.3. Ovarian Cancer
5.2.4. Non-Hodgkin Lymphoma
5.2.5. Prostate Cancer
5.2.6. Colorectal Cancer
5.2.7. Others (bladder cancer, lung cancer, etc.)
5.3. Autoimmune diseases
5.3.1. Systemic Sclerosis
5.3.2. Crohn’s Disease
5.3.3. Rheumatoid arthritis
5.3.4. Systemic Lupus Erythematous
5.3.5. Others (Sjogren's syndrome, multiple sclerosis, pernicious anemia, etc.)
5.4. Diabetes
5.5. Infectious diseases
5.6. Others (cardiovascular diseases, ophthalmic conditions, dermatological diseases, etc.)

Chapter 6. Global Biologics Market, by Geography, 2016-2026 (US$ Bn)
6.1. Overview
6.2. North America Biologics Market, 2016-2026 (US$ Bn)
6.2.1. North America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.2.2. North America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.2.3. North America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Biologics Market, 2016-2026 (US$ Bn)
6.3.1. Europe Biologics Market, by Product, 2016-2026 (US$ Bn)
6.3.2. Europe Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.3.3. Europe Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Biologics Market, 2016-2026 (US$ Bn)
6.4.1. Asia Pacific Biologics Market, by Product, 2016-2026 (US$ Bn)
6.4.2. Asia Pacific Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.4.3. Asia Pacific Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Biologics Market, 2016-2026 (US$ Bn)
6.5.1. Latin America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.5.2. Latin America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.5.3. Latin America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Biologics Market, 2016-2026 (US$ Bn)
6.6.1. Middle East & Africa (MEA) Biologics Market, by Product, 2016-2026 (US$ Bn)
6.6.2. Middle East & Africa (MEA) Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.6.3. Middle East & Africa (MEA) Biologics Market, by Region, 2016-2026 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Merck & Co. Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. AbbVie, Inc.
7.3. AstraZeneca Plc.
7.4. Amgen, Inc.
7.5. Celgene Corporation
7.6. Bristol-Myers Squibb Co.
7.7. Eli Lilly and Company
7.8. Janssen Pharmaceuticals, Inc.
7.9. GlaxoSmithKline Plc.
7.10. Novartis AG
7.11. Pfizer, Inc.
7.12. Novo Nordisk A/S
7.13. Sanofi S.A
7.14. Roche Holding AG
7.15. Takeda Pharmaceutical Co., Ltd

List of Figures
FIG. 1 Market Segmentation: Global Biologics Market
FIG. 2 Biologics Market: Research Methodology
FIG. 3 Global Biologics Market, by Product, 2016-2026 (US$ Bn)
FIG. 4 Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
FIG. 5 Global Biologics Market , by Geography, 2016-2026 (US$ Bn)
FIG. 6 Attractive Investment Proposition, by Geography, 2017
FIG. 7 Competitive Analysis: Global Biologics Market, by Key Players, 2017
FIG. 8 Global Monoclonal Antibodies Market, 2016-2026 (US$ Bn)
FIG. 9 Global Hormones Market, 2016-2026 (US$ Bn)
FIG. 10 Global Cytokines Market, 2016-2026 (US$ Bn)
FIG. 11 Global Enzymes Market, 2016-2026 (US$ Bn)
FIG. 12 Global Blood & Blood Components Market, 2016-2026 (US$ Bn)
FIG. 13 Global Cellular & Gene Therapy Market, 2016-2026 (US$ Bn)
FIG. 14 Global Vaccines Market, 2016-2026 (US$ Bn)
FIG. 15 Global Breast Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 16 Global Leukemia Market in Biologics, 2016-2026 (US$ Bn)
FIG. 17 Global Ovarian Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 18 Global Non-Hodgkin Lymphoma Market in Biologics, 2016-2026 (US$ Bn)
FIG. 19 Global Prostate Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 20 Global Colorectal Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 21 Global Other Cancers Market in Biologics, 2016-2026 (US$ Bn)
FIG. 22 Global Systemic Sclerosis Market in Biologics, 2016-2026 (US$ Bn)
FIG. 23 Global Crohn’s Disease Market in Biologics, 2016-2026 (US$ Bn)
FIG. 24 Global Rheumatoid Arthritis Market in Biologics, 2016-2026 (US$ Bn)
FIG. 25 Global Systemic Lupus Erythematous Market in Biologics, 2016-2026 (US$ Bn)
FIG. 26 Global Other Autoimmune Diseases Market in Biologics, 2016-2026 (US$ Bn)
FIG. 27 U.S. Biologics Market, 2016-2026 (US$ Bn)
FIG. 28 Canada Biologics Market, 2016-2026 (US$ Bn)
FIG. 29 U.K. Biologics Market, 2016-2026 (US$ Bn)
FIG. 30 Germany Biologics Market, 2016-2026 (US$ Bn)
FIG. 31 Rest of Europe Biologics Market, 2016-2026 (US$ Bn)
FIG. 32 Japan Biologics Market, 2016-2026 (US$ Bn)
FIG. 33 China Biologics Market, 2016-2026 (US$ Bn)
FIG. 34 Rest of Asia Pacific Biologics Market, 2016-2026 (US$ Bn)
FIG. 35 Brazil Biologics Market 2016-2026 (US$ Bn)
FIG. 36 Mexico Biologics Market 2016-2026 (US$ Bn)
FIG. 37 Rest of Latin America Biologics Market 2016-2026 (US$ Bn)
FIG. 38 GCC Biologics Market 2016-2026 (US$ Bn)
FIG. 39 Rest of MEA Biologics Market 2016-2026 (US$ Bn)

List of Tables
TABLE 1 Global Biologics Market Portraiture
TABLE 2 Global Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 3 Global Recombinant Therapeutic Proteins Market, by Class, 2016-2026 (US$ Bn)
TABLE 4 Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 5 Global Oncology Market, by Disease Type, 2016-2026 (US$ Bn)
TABLE 6 Global Autoimmune Diseases Market, by Disease Type, 2016-2026 (US$ Bn)
TABLE 7 Global Biologics Market , by Geography, 2016-2026 (US$ Bn)
TABLE 8 North America Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 9 North America Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 10 North America Biologics Market, by Country, 2016-2026 (US$ Bn)
TABLE 11 Europe Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 12 Europe Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 13 Europe Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
TABLE 14 Asia Pacific Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 15 Asia Pacific Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 16 Asia Pacific Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
TABLE 17 Latin America Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 18 Latin America Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 19 Latin America Biologics Market, by Country, 2016-2026 (US$ Bn)
TABLE 20 Middle East And Africa Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 21 Middle East And Africa Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 22 Middle East And Africa Biologics Market, by Region, 2016-2026 (US$ Bn)
TABLE 23 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 AbbVie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 AstraZeneca Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments) Amgen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Bristol-Myers Squibb Co. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Janssen Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 GlaxoSmithKline Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 33 Novo Nordisk A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 34 Sanofi S.A: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 35 Roche Holding AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 36 Takeda Pharmaceutical Co., Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck & Co. Inc.
  • AbbVie, Inc.
  • AstraZeneca Plc.
  • Amgen, Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Pfizer, Inc.
  • Novo Nordisk A/S
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll